Intranasal Administration of GDNF Protects Against Neural Apoptosis in a Rat Model of Parkinson's Disease Through PI3K/Akt/GSK3β Pathway

Neurochem Res. 2017 May;42(5):1366-1374. doi: 10.1007/s11064-017-2184-1. Epub 2017 Feb 28.

Abstract

Glial cell line-derived neurotrophic factor (GDNF) plays important roles in protecting the damaged or dying dopamine neurons in the animal models of Parkinson's disease (PD). This study was to determine the effect and mechanisms of GDNF on the apoptosis of neurons in 6-hydroxydopamine (6-OHDA) induced Parkinson's disease model of rats. Healthy male Sprague-Dawley rats (220-240 g) were randomly divided into six groups (n = 10). 6-OHDA was used to establish the PD rat model. Tyrosine hydroxylase (TH) immunohistochemistry was used to assess the neuron loss in 6-OHDA-lesioned rats. TUNEL and western blot were used to identify the effects and mechanisms of GDNF in the rat model of PD. The numbers of TH-positive neurons in the 6-OHDA-injected lesioned substantia nigra (SN) decreased significantly compared with the Sham group. GDNF treatment effectively ameliorated the apoptosis of neuronal cells in SN induced by 6-OHDA. In addition, GDNF significantly increased serine protein kinase B (Akt) and glycogen synthase kinase 3 beta (GSK3β) phosphorylation induced by 6-OHDA. In contrast, application of LY294002 or triciribine reversed the roles of GDNF in PD models. The results implicated that the anti-apoptosis effects of GDNF in neurons might be mediated through PI3K/Akt/GSK3β pathway. Therefore, GDNF may be a promising agent for PD treatment.

Keywords: Akt; Apoptosis; GDNF; GSK-3β; Parkinson’s disease.

MeSH terms

  • Administration, Intranasal
  • Animals
  • Apoptosis / drug effects
  • Apoptosis / physiology
  • Glial Cell Line-Derived Neurotrophic Factor / administration & dosage*
  • Glycogen Synthase Kinase 3 beta / antagonists & inhibitors
  • Glycogen Synthase Kinase 3 beta / metabolism*
  • Male
  • Neurons / drug effects
  • Neurons / metabolism*
  • Neurons / pathology
  • Neuroprotective Agents / administration & dosage
  • Oncogene Protein v-akt / antagonists & inhibitors
  • Oncogene Protein v-akt / metabolism*
  • Oxidopamine / toxicity
  • Parkinsonian Disorders / metabolism*
  • Parkinsonian Disorders / pathology
  • Parkinsonian Disorders / prevention & control
  • Phosphatidylinositol 3-Kinases / metabolism*
  • Phosphoinositide-3 Kinase Inhibitors
  • Rats
  • Rats, Sprague-Dawley
  • Substantia Nigra / drug effects
  • Substantia Nigra / metabolism
  • Substantia Nigra / pathology

Substances

  • Gdnf protein, rat
  • Glial Cell Line-Derived Neurotrophic Factor
  • Neuroprotective Agents
  • Phosphoinositide-3 Kinase Inhibitors
  • Oxidopamine
  • Glycogen Synthase Kinase 3 beta
  • Oncogene Protein v-akt